Multiple Indications | Special Topics | COPD and Asthma | G7 | 2017
Device choice has long been a driver of sales of certain inhaled therapies, especially those available in multiple inhalers. With generic LAMAs and LABA/ICS FDCs anticipated to launch in the United States, devices may become an even more important driver of physician choice among respiratory therapies. Surveyed and interviewed practitioners note that while insurance often constrains their prescribing options, the device used with a therapy is an important driver and will become even more important as generic drug/device combinations become available. Unmet needs in the device market remain, especially for simpler devices and improved lung deposition.
Questions Answered:
- What are the treatment drivers and goals for asthma and COPD?
- What drug/device attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current drug/device combinations perform on key treatment drivers and goals for asthma and COPD?
- What are the prevailing areas of unmet need and opportunity in drug/device combinations for asthma and COPD?
- What trade-offs across different clinical attributes and price are acceptable to U.S. pulmonologists for a hypothetical new drug/device combination for asthma and COPD?
Markets covered: United States
Primary research: Survey of 60 U.S. pulmonologists fielded in March 2017
Key companies: GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Teva, Mylan, Propeller Health
Key drugs: Spiriva HandiHaler, Spiriva Respimat, Anoro Ellipta, Brovana, Symbicort HFA, Advair HFA, Advair Diskus
